CAITLYN WONNING: Open Payments
NPI 1285346023 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,000 in 69 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $610 · 2025 $1,000
Food & beverage: $1,000
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $452 |
| Novo Nordisk Inc | 7 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $103 |
| PFIZER INC. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Lundbeck LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: VRAYLAR, QULIPTA, UBRELVY, CAPLYTA, REXULTI, NURTEC ODT, Ozempic, Wegovy.
Industry payments across IN — which companies pay providers there.
